

# ASX ANNOUNCEMENT

21 December 2021



## OPERATIONAL UPDATE

### CANN GLOBAL RECEIVES INSTACANN THC 5MG SHIPMENT AND LAUNCHES FUSS POT

Cann Global Limited (ASX: CGB) (“Cann Global” or “the Company”) announces that a second shipment of Canntab products has been received in the country. This shipment includes the Instacann THC 5mg product for the first time which is now available for patients to buy on prescription. Information on Instacann continues to be rolled out to general practitioners to build awareness of product availability and includes information on the newly available THC 5mg product. More information on the Canntab products can be found on our website ([www.canngloballimited.com/canntab](http://www.canngloballimited.com/canntab)).

The soft launch of the Company’s premium plant-based skincare range Fuss Pot occurred in Australia at the Hemp Health & Innovation Expo in November following an earlier launch in Paris at the CBD Expo which generated significant international interest. Orders are now being received online through the website ([www.imafusspot.com](http://www.imafusspot.com)) and products are being dispatched from our new warehouse facility in Brisbane.

Our new health food brand Grass Roots is progressing well and will launch in Q3 FY22. This initiative is part of a larger project focused on product rationalisation, and a focus on brands and distribution which will optimise revenue margins and therefore profits. The new brand will range our existing products and some new products currently being developed with an expert dietician.

The Company’s Annual General Meeting will be held in January 2022 taking advantage of ASIC’s extension and we will advise shareholders of the date in the near term as the Notice of Meeting is dispatched.

Further information on the Company’s operations will be provided in the quarterly report to be released on or before January 27 2022.

#### ABOUT CANNGLOBAL

Cann Global Limited (ASX:CGB) is a driving force in the hemp and medical Cannabis industries. Our strength comes from our team’s core competencies and expertise, and our solid and strategic partnerships with experts in Australia, USA, Israel, Asia, Africa and Canada. We are working under the relevant legislation to ensure that the future in Medical Cannabis and Natural Foods will allow medical practitioners, patients, and consumers to gain access to the right information, as well as the safest, most effective and sustainable products.

Level 21, 133 Castlereagh Street,  
Sydney NSW 2000 - Australia

Telephone: (02) 8379 1832

[investorrelations@cannglobal.com.au](mailto:investorrelations@cannglobal.com.au)

[www.cannglobal.com.au](http://www.cannglobal.com.au)

# ASX ANNOUNCEMENT



## AUTHORITY AND CONTACT DETAILS

This announcement has been authorised for release by Sholom Feldman, Managing Director. For further information please contact Investor Relations on +61 (0)2 8379 1832, or via email at [investorrelations@cannglobal.com.au](mailto:investorrelations@cannglobal.com.au)